Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update
by Mitch Edgeman · The Markets DailyNovozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totaling 3,603 shares, a decrease of 86.4% from the July 15th total of 26,584 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 47,927 shares, the days-to-cover ratio is presently 0.1 days.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on the company. Zacks Research raised Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Kepler Capital Markets upgraded Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy”.
Check Out Our Latest Research Report on NVZMY
Novozymes A/S Stock Performance
Shares of OTCMKTS NVZMY traded up $1.40 during midday trading on Friday, reaching $65.58. The company’s stock had a trading volume of 51,488 shares, compared to its average volume of 71,130. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.67 and a quick ratio of 1.03. Novozymes A/S has a 12-month low of $49.90 and a 12-month high of $66.66. The stock has a market capitalization of $27.19 billion, a P/E ratio of 44.31, a PEG ratio of 3.00 and a beta of 0.92. The firm has a 50 day moving average price of $62.85 and a 200-day moving average price of $60.45.
Institutional Trading of Novozymes A/S
An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B boosted its position in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.
Novozymes A/S Company Profile
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).